tradingkey.logo

Crispr Therapeutics Reports Positive Additional Phase 1 Data For Ctx310™ Targeting Angptl3 And Provides Update On In Vivo Cardiovascular Pipeline

ReutersJun 26, 2025 11:04 AM

- CRISPR Therapeutics AG CRSP.BN:

  • CRISPR THERAPEUTICS REPORTS POSITIVE ADDITIONAL PHASE 1 DATA FOR CTX310™ TARGETING ANGPTL3 AND PROVIDES UPDATE ON IN VIVO CARDIOVASCULAR PIPELINE

  • CRISPR THERAPEUTICS AG - CTX310 SHOWS UP TO 82% TG AND 86% LDL REDUCTION

  • CRISPR THERAPEUTICS AG - CTX320 DATA UPDATE EXPECTED IN H1 2026

  • CRISPR THERAPEUTICS AG - COMPLETE PHASE 1 DATA FOR CTX310 EXPECTED IN H2 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI